RT Journal Article
T1 Analysis of the Costs Associated With the Elective Evaluation of Patients Labelled as Allergic to Beta-Lactams or Nonsteroidal Antiinflamatory Agents
A1 Sobrino-García, Miriam
A1 Moreno, Esther M.
A1 Muñoz-Bellido, Francisco J.
A1 Gracia-Bara, Maria T.
A1 Laffond, Elena
A1 Doña, Inmaculada
A1 Martín, Cristina
A1 Macías, Eva M.
A1 de Arriba, Sonia
A1 Campanón, Valle
A1 Gallardo, Alicia
A1 Dávila, Ignacio
K1 Beta-lactam
K1 Cost
K1 Delabelling
K1 Drug hypersensitivity
K1 Non-steroidal anti-inflammatory drug
K1 Penicillin
K1 Drug allergy
K1 Beta-lactamas
K1 Costos y análisis de costo
K1 Hipersensibilidad a las drogas
K1 Antiinflamatorios no esteroideos
K1 Penicilinas
AB Introduction: Being labelled as allergic to different drugs results in patients receiving other treatments, which are more toxic, less effective and more expensive. We aimed to analyze different studies of the costs of drug hypersensitivity assessment. Methods: A bibliographic search on studies regarding this issue was performed, including the available scientific evidence up to June 2020. We searched three databases with terms related to costs and allergy testing in drug hypersensitivity reactions. Results: Our search revealed 1,430 publications, of which 20 met the inclusion criteria. In the manuscript, prospective studies evaluating the costs of the evaluation of patients with suspected allergy to beta-lactams or non-steroidal anti-inflammatory drugs are analyzed. Also, comment is made on the costs associated with incorrect labeling as non-steroidal anti-inflammatory drug or penicillin hypersensitivity. Conclusions: Taking all costs into account, the study of drug hypersensitivity is not expensive, particularly considering the economic and clinical consequences of labeling a patient with hypersensitivity to drugs.
PB Frontiers
YR 2020
FD 2020-11-30
LK http://hdl.handle.net/10668/3838
UL http://hdl.handle.net/10668/3838
LA en
NO Sobrino-García M, Moreno EM, Muñoz-Bellido FJ, Gracia-Bara MT, Laffond E, Doña I, et al. Analysis of the Costs Associated With the Elective Evaluation of Patients Labelled as Allergic to Beta-Lactams or Nonsteroidal Antiinflamatory Agents. Front Pharmacol. 2020 Nov 30;11:584633
DS RISalud
RD Apr 11, 2025